|Publication number||US3640896 A|
|Publication date||Feb 8, 1972|
|Filing date||Apr 13, 1970|
|Priority date||Apr 13, 1970|
|Publication number||US 3640896 A, US 3640896A, US-A-3640896, US3640896 A, US3640896A|
|Inventors||Casperis Anthony J De|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (35), Classifications (8), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States US. Cl. 252408 1 Claim ABSTRACT OF THE DISCLOSURE A diagnostic composition serving as a multiple-analysis hematology reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of the co-pending US. application Ser. No. 802,263, filed Feb. 25, 1969.
BACKGROUND OF THE INVENTION This invention relates to a diagnostic hematology composition. More particularly, it relates to a stabilized and standardized suspension of blood cells that provides a reference control for a number of routine hematologic determinations.
Up to now, the prior art of hematology determinations has suffered from the lack of stable reference controls. With the advent of automated devices capable of performing multiple hematological determinations, a growing need has developed for cross reference samples for manual and automated machine analyses.
The distinguishing feature of this invention resides in the preparation of a stable multiple-analysis reference control which combines in a single composition reference controls for red blood cell and white blood counting, hemoglobin content, hematocrit determination, and allows by mathematical computation, the calculation of mean corpuscular volume and mean corpuscular hemoglobin, concentration, and mean corpuscular hemoglobin.
An embodiment of this invention is the preparation of a stable cell suspension that approximates the composition of normal human blood. Oxalated or citrated whole human blood has limited stability on storage. Red blood cells slowly hemolyze and undergo changes in size and shape. Similarly, white blood cells suffer degenerative changes.
A novel feature of this invention is the preparation of a stable red blood cell suspension that serves as a reference control for human white blood cells. Human white blood cells are not suitable for control purposes, especially in the presence of red blood cells, because they are unstable, excreting a lysozyme type of enzyme that attacks red blood cells. Avian red blood cells are larger than human red blood cells, and approximate the size and shape of human white blood cells. For purposes of this invention it has been found that fowl red blood cells such as goose, chicken, duck, and preferably turkey red blood cells, closely match the size and shape of human white blood cells, and lend themselves nicely to the subject tanning process. These stabilized simulated white blood cells provide a satisfactory substitute for human white blood cells in our composition control product.
It has been found that fresh human red blood cells, stabilized by suspension in human plasma or serum with added metabolic preservative, satisfactorily provide the red blood cells component of the subject composition. Plasma or serum provide some of the necessary electroatent O" 3,640,896 Patented Feb. 8, 1972 ice lytes and proteins necessary for red blood metabolic stability. Selected purines or pyrimidines act as additional metabolic preservatives.'The untanned red blood cells are readily hemolyzed in the prior operational step for the white blood cell count and subsequent hemoglobin determination.
Suspensions of human red blood cells and simulated white blood cells are mixed in such proportion that the final red blood cell and White blood cell counts, hemoglobin content and hematocrit fall in the range considered normal for human blood.
The normal range in human blood for red blood cells is 4,000,0005,000,000 cells/mm. and for white blood cells the count is 5,000l0,000 cells/mm The normal hemoglobin value is 12-16 grams/ ml. The term hematocrit is defined as the ratio of volume of packed red blood cells to the volume of whole blood. The normal ratio in humans is about 45%. The mean corpuscular volume is the ratio of the volume of packed red cells in ml. per liter of blood to red blood cells in millions per cubic millimeter. The mean corpuscular hemoglobin concentration is an index indicating the mean or average weight of hemoglobin per 100 ml. of packed red blood cell in terms of percent. The mean corpuscular hemoglobin is the ratio of hemoglobin content in grams per liter to red blood cells per cubic millimeter.
It is evident that a control product must accurately indicate on a comparative basis What a test sample of blood constitutes with regard to the above determinations. It is further evident how important it is for the control product to simulate non-treated cells. It follows, for instance, that if the control product contains cells that differ materially in size, the experimental results will be inaccurate, if not wholly meaningless. In essence, the cells treated by the method disclosed herein provides an excellent system of checks and balances so necessary in hematologic determinations.
SUMMARY OF THE INVENTION cell counting, hemoglobin content and hematocrit determination.
DETAILED DESCRIPTION OF THE INVENTION Regarding the novel methods to be described, it is to be understood that the term saline throughout can be any of the following three solutions: 0.9% by weight aqueous sodium chloride solution which is designated by the term solution A; 0.45% by weight aqueous sodium chloride solution designated as solution B; or a buffered saline solution (solution C). In most instances, the 0.9% solution (solution A) is implied when reference is made to the term saline. Isoton (Coulter Electronic, Hialeah, Florida) is an isotonic solution of buffer salts, pH 7.2.
The preparation of red blood cells for a white blood cell reference control presents special problems. Fowl red blood cells are preferred and turkey red blood cells in particular are most preferred. However, it is to be understood that fowl cells such as goose, chicken and duck will provide effective products. The fowl red blood cells are first washed several times with 0.45% w./v. sodium chloride solution and then suspended in 0.45 saline solution prior to the stabilizing treatment. This saline concentration swells the cells so that they closely resemble human white blood cells in size and shape. The size and shape are maintained after the subsequent stabilizing treatment.
The second step of the herein disclosed method consists of suspending fowl red blood cells in a saline suspension to provide up to 50% by volume suspension. Although a concentration as high as 50% will work, it is preferred to use a range from to by volume, and even more preferred to use an 8% suspension. This suspension is combined with an equal volume of 1 to 3% solution by weight of mercuric chloride in saline. Mercuric chloride was found to be clearly superior to formaline, giving a more stable red blood cell and, most importantly, the shape of the red blood cell is retained.
The third step consists of heating the resulting mixture at 37 C. for at least 12 hours, and preferably, for about hours. The solid materials are recovered by centrifugation and separation, and then resuspended in saline.
The fourth step consists of combining with the aforesaid suspension, an equal volume of a 0.0025% w./v. solution of aqueous tannic acid in saline with thorough mixing, incubating the resulting mixture for about to minutes at about 50 C. (this temperature is critical) and recovering the solid product by centrifugation and separation. Regarding this saline solution containing the tannic acid, it is the only instance in the herein disclosed invention wherein saline solution C described earlier is utilized. It is a buffered saline solution having a pH of 7.2. Its preparation consists of combining the following reagents in the proportions indicated (per liter):
0.9% saline 500 0.15 M disodium phosphate 385 0.15 M monopotassium phosphate 115 Further fixation of the fowl red blood cells is accomplished by treating a 0.01 to 20.0% by volume suspension of the tanned cells in a 2 l0% w./v., preferably 5% w./v.
solution of glutaraldehyde in Isoton. The cell suspension is incubated at 37 C. for about 16-20 hours, centrifuged, washed 3-4 times with Isoton and then reconstituted in Isoton.
The preparation of the human red blood cell suspension is carried out under sterile conditions. For this purpose, red blood cells from any blood type can be used. However, Group 0 blood cells are preferably used because of the ready availability of blood donors of this type. Pooled Group 0 blood, collected in acid citrate-dextrose anticoagulant solution, is centrifuged, the supernatant removed and set aside, and the buffy layer of white blood cells gently removed and discarded. The packed red blood cells are washed several times with Alsevers solution, reconstituted in serum diluted 1:3 with Alsevers solution and stored at 28 C. Alternately, the packed red blood cells are washed several times with Isoton and resuspended in undiluted defibrinated plasma.
The reisuspending medium, used for the final suspension of the human red blood cells, is prepared from defibrinated plasma that is serologically compatible with the suspended human red blood cells, i.e., Group A cells with plasma from Group A, Group B cells with plasma from Group B and Group 0 cells with plasma from Group 0. Defibrinated Group AB plasma (lacking antibodies A and B) is compatible with Group A, Group B and Group 0 red blood cells. These plasma supernatants are defibrinated by treatment with bovine thrombin and used directly, or diluted 1:3 with Alsevers solution.
As a further stability aid for the fresh human red blood cells component of the final cell suspension, a metabolic preservative, selected from the class of compounds comprising purines and pyrmidines, is added to the suspending medium at a final concentration of about 34-35 mg. per 100 ml. of cell suspension.
A particularly effective preservative agent is adenine (6-aminopurine or a pharmaceutically acceptable acid additon salt, Mann Research Laboratories, Inc., New York, N.Y.).
The following examples are merely illustrative and are not intended to limit the invention, the scope of which is definedby the appended claim.
4 Example I Group 0 blood, collected in aqueous acid citratedextrose anticoagulant, is centrifuged under sterile conditions at 2000 rpm. for 20 minutes. The supernatant is gently suctioned off, care being taken not to draw into the supernatant any of the red cells or buify white layer at the interface of the red cells and supernatant. The supernatant is defibrinated and retained as such or after dilution with Alsevers solution used as a resuspending medium.
The bulfy layer (white blood cells) is carefully removed from the top of the packed red blood cells, Withdrawing a thin surface of red cells if necessary. The packed red cells are washed twice with Alsevers solution, centrifuged and stored at 2-8 C. until subsequent mixture with stabilized simulated white blood cells and reconstituted with defibrinated plasma diluted 1:3 with Alsevers. Alternately, the packed red cells are washed several times with Isoton, centrifuged and resuspended in undiluted defibrinated plasma.
Example 11 Fowl red blood cells, preferably turkey cells, which are collected in Alsevers solution, are Washed 3 times in saline (solution B, 0.45% w./v.) 3300 r.p.m./5 minutes each washing, and after the final wash are resuspended as an 8% by volume suspension in saline (solution B). To 100 ml. of this 8% suspension fowl (turkey) red blood cells is added 100 ml. of a 1% solution by weight of mercuric chloride in saline (solution A) and the resulting suspension is thoroughly mixed. The suspension is incubated at 37 C. for 18-20 hours, without disturbing the cells, the thin murky layer resting on top of the settled cells is suctioned off. The suspension is then centrifuged, washed 4 times with distilled water (3300 r.p.rn./5 minutes each washing), and rcsuspended in saline (solution A) as a 4% by volume suspension. To this 4% suspension is added an equal volume of a 0.0025% W./v. solution of tannic acid in bulfered saline (solution C) and the resulting mixture thoroughly mixed, incubated at 50 C. for about 30 to 60 minutes, allowed to stand at room temperature for 18-20 hours, centrifuged, and washed 3 times with distilled water. A 0.0120.0% by volume suspension of the tanned cells is a 5.0% W./v. of glutaraldehyde in Isoton is incubated at 37 C. for about 1620 hours, centrifuged and washed 3-4 times with lsoton.
Example III The supernatant plasma, obtained from Group 0 bloods collected in aqueous acid citrate-dextrose anticoagulant, is defibrinated by adding bovine thrombin (Parke-Davis & Co., Detroit, Mich.) at a concentration of 1 unit/ml, and incubated at 37 C. for 1 hour. The clotted material is shaken vigorously to break up the clot, and filtered through a No. 50 Whatman filtered pad on a Buchner funnel-suction flask set-up. Adenine sulfate is added at a concentration of 70 mg./100 ml., warming at 37 C. to hasten to dissolution, and the solution filtered successively through 0.45 and 0.22 millipore filter pads.
Example IV The method of Example III with plasma from Group AB blood in place of Group G plasma.
Example V The simulated white blood cells prepared by the method of Example II are reconstituted in the plasma suspending medium or sterile Alsevers solution to about a 24% hematocrit. This has an approximate count of 750,000800,000 cells/mmfi. Two ml. of this suspension is further diluted by the addition of 100 ml. of the resuspending medium as prepared by the method of Example H1 or Example IV.
To a volume of packed human Group 0 blood cells (approximately hematocrit) prepared by the method of Example I, is added an equal volume of the diluted simulated white 'blood cells suspension referred to above.
The final cell suspension product, containing approximately 34-35 mg./ 100 ml. of adenine, has a red blood cell count of about 4,000,000-5,000,000 cells/mmfi, white blood cell count of 5,000-10,000 cells/mm, hemoglobin, 12-16 grams/ 100 ml. and hematocrit, 43-47%.
Aliquots (2.5 ml.) of the final suspension product, dispensed in glass vials, are stable for approximately 4 weeks when stored at 28 C.
What is claimed is:
1. The method for stabilizing the fowl red blood cells which comprises:
(a) commingling a suspension of fowl red blood cells in 0.45% saline wherein said cells comprise about 8% by volume of said suspension, and an equal volume of a 1% solution by weight of mercuric chloride in 0.45 saline;
(b) heating the resulting mixture at 37 C. for about 19 hours, recovering and resuspending the solid materials as a 4% by volume suspension in saline; and
(c) combining therewith an equal volume of a 0.0025 weight/volume solution of tannic acid in saline, incubating the resulting mixture for about 30 to 60 minutes at about 50 C. and
(d) incubating a 0.0=1-20.0% by volume suspension of the cells in a 5.0% w./v. solution of glutaraldehyde in an isotonic solution buffered at pH 7.2 at 37 C. for 16-20 hours, washing 3-4 times with said buffered isotonic solution and recovering the solid product.
References Cited UNITED STATES PATENTS 3,519,572 7/1970 Kita 252-408 JOHN T. GOOLKASIAN, Primary Examiner M. E. McCAMISH, Assistant Examiner U.S. Cl. X.R. 23-230 B; 4242
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3873467 *||Feb 1, 1974||Mar 25, 1975||United Medical Lab Inc||Hematologic reference control|
|US3977995 *||Oct 17, 1974||Aug 31, 1976||Baxter Laboratories, Inc.||Calibrating fluid for blood cell counting and hemoglobin determination|
|US4007008 *||Jul 30, 1975||Feb 8, 1977||Becker Milton J||Preparation of reference serum from animal blood|
|US4160644 *||Jun 13, 1977||Jul 10, 1979||Streck Laboratories, Inc.||Platelet reference control and method of preparation|
|US4179398 *||Mar 21, 1977||Dec 18, 1979||ICN Medical Laboratories, Inc.||Platelet control composition|
|US4198206 *||Aug 30, 1978||Apr 15, 1980||Ryan Wayne L||Method for preparing a platelet reference control|
|US4206077 *||Aug 29, 1978||Jun 3, 1980||Djuro Rodjak||Agent for facilitating the counting of thrombocytes in blood samples|
|US4219440 *||Jun 6, 1979||Aug 26, 1980||Coulter Electronics, Inc.||Multiple analysis hematology reference control reagent and method of making the same|
|US4250051 *||Dec 26, 1978||Feb 10, 1981||Coulter Electronics, Inc.||Preservative for use in calibrator compositions for blood analysis|
|US4302355 *||Mar 4, 1980||Nov 24, 1981||Warner-Lambert Company||Platelet reference control|
|US4579824 *||May 18, 1983||Apr 1, 1986||Louderback Allan Lee||Hematology control|
|US4632907 *||Aug 19, 1985||Dec 30, 1986||Shionogi & Co., Ltd.||Preservative solution for fixed avian erythrocytes for the viral hemagglutination test|
|US4727042 *||May 24, 1984||Feb 23, 1988||Southeast Vetlab Inc.||Calibrator composition and method of producing and using same for veterinary applications|
|US4867908 *||Jun 4, 1987||Sep 19, 1989||Becton, Dickinson And Company||Method and materials for calibrating flow cytometers and other analysis instruments|
|US5039487 *||May 3, 1990||Aug 13, 1991||Board Of Regents, The University Of Texas System||Methods for quantifying components in liquid samples|
|US5672474 *||Nov 26, 1996||Sep 30, 1997||Streck Laboratories, Inc.||White blood cell hematology control|
|US5677145 *||Sep 25, 1996||Oct 14, 1997||Streck Laboratories, Inc.||White blood cell hematology control|
|US5731205 *||Jan 21, 1997||Mar 24, 1998||Streck Laboratories, Inc.||White blood cell hematology control|
|US5981282 *||Jan 21, 1997||Nov 9, 1999||Streck Laboratories, Inc.||White blood cell hematology control|
|US5994139 *||Apr 7, 1998||Nov 30, 1999||Coulter International Corp.||Stable hematology control composition and method of use|
|US6200500||Aug 20, 1999||Mar 13, 2001||Streck Laboratories, Inc.||Hematology control and system for multi-parameter hematology measurements|
|US6221668||Feb 16, 2000||Apr 24, 2001||Streck Laboratories, Inc.||Hematology control and system for multi-parameter hematology measurements|
|US6399388||Dec 19, 2000||Jun 4, 2002||Streck Laboratories, Inc.||Hematology control and system for multi-parameter hematology measurements|
|US6403377||Aug 21, 2001||Jun 11, 2002||Streck Laboratories, Inc.||Hematology control and system for multi-parameter hematology measurements|
|US6406915||Aug 21, 2001||Jun 18, 2002||Streck Laboratoreis, Inc.||Hematology control and system for multi-parameter hematology measurements|
|US6509192 *||Jan 22, 1997||Jan 21, 2003||Coulter International Corp.||Quality control method|
|US6653137||Dec 3, 2001||Nov 25, 2003||Streck Laboratories Inc.||Hematology reference control|
|US6723563||Dec 3, 2001||Apr 20, 2004||Streck Laboratories Inc.||Hematology reference control|
|US20030092184 *||Aug 9, 2002||May 15, 2003||Coulter International Corporation||Quality control method|
|US20050048656 *||Aug 2, 2004||Mar 3, 2005||Young Carole J.||Quality control method|
|US20050048657 *||Aug 2, 2004||Mar 3, 2005||Young Carole J.||Method of using a hematology control product|
|US20050095719 *||Nov 24, 2004||May 5, 2005||Young Carole J.||Quality control method|
|US20050221496 *||May 25, 2005||Oct 6, 2005||Young Carole J||Quality control method|
|US20050221497 *||May 25, 2005||Oct 6, 2005||Carole Young||Quality control method|
|EP0258257A1 *||May 22, 1986||Mar 9, 1988||Streck Laboratories, Inc.||Glucose reference control for glucose test strips|
|U.S. Classification||436/10, 436/18, 436/17, 436/15|
|Cooperative Classification||G01N33/96, G01N2496/05|
|May 14, 1981||AS02||Assignment of assignor's interest|
Owner name: PFIZER INC.
Effective date: 19810409
Owner name: WARNER-LAMBERT COMPANY, 201 TABOR RD., MORRIS PLAI
|May 14, 1981||AS||Assignment|
Owner name: WARNER-LAMBERT COMPANY, 201 TABOR RD., MORRIS PLAI
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:PFIZER INC.;REEL/FRAME:003853/0905
Effective date: 19810409